Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. | Delanoy, N ; Hardy-Bessard, AC ; Efstathiou, E ; Le Moulec, S ; Basso, U ; Birtle, A & al | Eur Urol Oncol | 2018 | 1 | 467–475 | 31158090 |
[Nausea and vomiting induced by chemotherapy]. | Scotté, F ; Chastenet, M ; Leroy, P ; Aumont, L ; Goudiaby, C ; Legeay, K & al | Rev Prat | 2019 | 69 | 49–54 | 30983284 |
[Supportive care in oncology: definition, organization, limits]. | Scotté, F ; Chastenet, M ; Leroy, P ; Aumont, L ; Goudiaby, C ; Legeay, K & al | Rev Prat | 2019 | 69 | 33–38 | 30983282 |
[Primary prophylaxis of venous thromboembolism in ambulatory cancer patients treated with antineoplastic agents]. | Debourdeau, P ; Simonin, C ; Carbasse, C ; Debourdeau, T ; Zammit, C ; Scotté, F | Rev Med Interne | 2019 | | | 30928244 |
Side effects of immunotherapy: a constant challenge for oncologists. | Scotté, F ; Ratta, R ; Beuzeboc, P | Curr Opin Oncol | 2019 | 31 | 280–285 | 30925538 |
[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines]. | Jovenin, N ; Eche-Gass, A ; Chèze, S ; Launay-Vacher, V ; Mayeur, D ; Rey, JB & al | Bull Cancer | 2019 | 106 | 497–509 | 30922554 |
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. | Oudard, S ; Latorzeff, I ; Caty, A ; Miglianico, L ; Sevin, E ; Hardy-Bessard, AC & al | JAMA Oncol | 2019 | 5 | 623–632 | 30703190 |
Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. | Scotté, F ; Leroy, P ; Chastenet, M ; Aumont, L ; Benatar, V ; Elalamy, I | Cancers (Basel) | 2019 | 11 | | 30621020 |
Spinal cord stimulation for chronic refractory pain: Long-term effectiveness and safety data from a multicentre registry. | Brinzeu, A ; Cuny, E ; Fontaine, D ; Mertens, P ; Luyet, PP ; Van den Abeele, C & al | Eur J Pain | 2019 | 23 | 1031–1044 | 30597719 |
Patient-reported outcomes (PROs) as a routine measure for cancer inpatients: the final missing piece of the puzzle? | Brandt, J ; Scotté, F ; Jordan, K | Ann Oncol | 2019 | 30 | 167–169 | 30481270 |
[French ccAFU guidelines — Update 2018–2020: Prostate cancer]. | Rozet, F ; Hennequin, C ; Beauval, JB ; Beuzeboc, P ; Cormier, L ; Fromont-Hankard, G & al | Prog Urol | 2018 | 28 | S79-S130 | 30392712 |
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. | Necchi, A ; Pond, GR ; Moschini, M ; Plimack, ER ; Niegisch, G ; Yu, EY & al | Clin Genitourin Cancer | 2019 | 17 | 7–14.e3 | 30292628 |
French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. | Briot, K ; Paccou, J ; Beuzeboc, P ; Bonneterre, J ; Bouvard, B ; Confavreux, CB & al | Joint Bone Spine | 2019 | 86 | 21–28 | 30287350 |
[Impact of beauty and well-being care assessed in a national survey including 1166 individuals]. | Saghatchian, M ; Bouleuc, C ; Naudet, C ; Arnaud, S ; Papazian, P ; Scotté, F & al | Bull Cancer | 2018 | 105 | 671–678 | 30099993 |
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. | Arantes, LH ; Crawford, J ; Gascon, P ; Latymer, M ; Launay-Vacher, V ; Rolland, C & al | Crit Rev Oncol Hematol | 2018 | 129 | 79–90 | 30097240 |
Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. | Mauge, L ; Mejean, A ; Fournier, L ; Pereira, H ; Etienne-Grimaldi, MC ; Levionnois, E & al | Clin Cancer Res | 2018 | 24 | 5534–5542 | 30061359 |
Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. | Larkin, PJ ; Cherny, NI ; La Carpia, D ; Guglielmo, M ; Ostgathe, C ; Scotté, F & al | Ann Oncol | 2018 | 29 | iv111-iv125 | 30016389 |
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. | Sonpavde, GP ; Mariani, L ; Lo Vullo, S ; Raggi, D ; Giannatempo, P ; Bamias, A & al | J Urol | 2018 | 200 | 1207–1214 | 30012366 |
Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. | Scotté, F ; Bossi, P ; Carola, E ; Cudennec, T ; Dielenseger, P ; Gomes, F & al | Ann Oncol | 2018 | 29 | 1718–1726 | 30010772 |
Peritoneal tuberculosis associated with adrenocorticol primitive neoplasm mimicking a peritoneal carcinosis: a case report. | Lamuraglia, M ; Barrascout, E ; Medioni, J | Eur J Gynaecol Oncol | 2016 | 37 | 543–545 | 29894081 |
Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. | Kanesvaran, R ; Le Saux, O ; Motzer, R ; Choueiri, TK ; Scotté, F ; Bellmunt, J & al | Lancet Oncol | 2018 | 19 | e317-e326 | 29893263 |
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. | Meyer, E ; Pasquier, D ; Bernadou, G ; Calais, G ; Maroun, P ; Bossi, A & al | Eur J Cancer | 2018 | 98 | 38–47 | 29864737 |
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. | Méjean, A ; Ravaud, A ; Thezenas, S ; Colas, S ; Beauval, JB ; Bensalah, K & al | N Engl J Med | 2018 | 379 | 417–427 | 29860937 |
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. | Aparicio, T ; Ducreux, M ; Faroux, R ; Barbier, E ; Manfredi, S ; Lecomte, T & al | Eur J Cancer | 2018 | 98 | 1–9 | 29807237 |
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. | Thibault, C ; Eymard, JC ; Birtle, A ; Krainer, M ; Baciarello, G ; Fléchon, A & al | Eur J Cancer | 2018 | 97 | 41–48 | 29636272 |
Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. | Vano, YA ; Oudard, S ; By, MA ; Têtu, P ; Thibault, C ; Aboudagga, H & al | PLoS One | 2018 | 13 | e0195042 | 29624591 |
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. | André, T ; Vernerey, D ; Mineur, L ; Bennouna, J ; Desrame, J ; Faroux, R & al | J Clin Oncol | 2018 | 36 | 1469–1477 | 29620995 |
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. | Outh-Gauer, S ; Alt, M ; Le Tourneau, C ; Augustin, J ; Broudin, C ; Gasne, C & al | Cancer Treat Rev | 2018 | 65 | 54–64 | 29547766 |
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. | Smith, MR ; Saad, F ; Chowdhury, S ; Oudard, S ; Hadaschik, BA ; Graff, JN & al | N Engl J Med | 2018 | 378 | 1408–1418 | 29420164 |
Physicians” decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France. | Scotté, F ; Elalamy, I ; Mayeur, D ; Meyer, G | Support Care Cancer | 2018 | 26 | 2049–2056 | 29353416 |
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. | Perez-Gracia, JL ; Loriot, Y ; Rosenberg, JE ; Powles, T ; Necchi, A ; Hussain, SA & al | Eur Urol | 2017 | | | 29273410 |
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. | Palle, J ; Tougeron, D ; Pozet, A ; Soularue, E ; Artru, P ; Leroy, F & al | Oncotarget | 2017 | 8 | 101383–101393 | 29254172 |
European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. | Jordan, K ; Aapro, M ; Kaasa, S ; Ripamonti, CI ; Scotté, F ; Strasser, F & al | Ann Oncol | 2018 | 29 | 36–43 | 29253069 |
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn”s Disease. | Beaugerie, L ; Carrat, F ; Nahon, S ; Zeitoun, JD ; Sabaté, JM ; Peyrin-Biroulet, L & al | Clin Gastroenterol Hepatol | 2018 | 16 | 892–899.e2 | 29199142 |
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. | Loriot, Y ; Pagliaro, L ; Fléchon, A ; Mardiak, J ; Geoffrois, L ; Kerbrat, P & al | Eur J Cancer | 2017 | 87 | 140–146 | 29149760 |
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. | Lavaud, P ; Gravis, G ; Foulon, S ; Joly, F ; Oudard, S ; Priou, F & al | Eur Urol | 2018 | 73 | 696–703 | 29074061 |
A Practical Approach to Fatigue Management in Colorectal Cancer. | Aapro, M ; Scotte, F ; Bouillet, T ; Currow, D ; Vigano, A | Clin Colorectal Cancer | 2017 | 16 | 275–285 | 29066018 |
Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists. | Mahé, I ; Scotté, F ; Rey, JB ; Elalamy, I ; Lamblin, A ; Mayeur, D & al | J Med Vasc | 2017 | 42 | 255–262 | 28964384 |
Radium 223 dichloride for prostate cancer treatment. | Deshayes, E ; Roumiguie, M ; Thibault, C ; Beuzeboc, P ; Cachin, F ; Hennequin, C & al | Drug Des Devel Ther | 2017 | 11 | 2643–2651 | 28919714 |
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. | Necchi, A ; Mariani, L ; Lo Vullo, S ; Yu, EY ; Woods, ME ; Wong, YN & al | Eur Urol Focus | 2019 | 5 | 242–249 | 28753897 |
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist”s Perspective from a Multicentre Study. | Necchi, A ; Pond, GR ; Smaldone, MC ; Pal, SK ; Chan, K ; Wong, YN & al | Eur Urol Focus | 2018 | 4 | 937–945 | 28753879 |
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. | Lamy, PJ ; Allory, Y ; Gauchez, AS ; Asselain, B ; Beuzeboc, P ; de Cremoux, P & al | Eur Urol Focus | 2018 | 4 | 790–803 | 28753865 |
Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy. | Grellier Adedjouma, N ; Chevrier, M ; Fourquet, A ; Costa, E ; Xu, H ; Berger, F & al | Int J Radiat Oncol Biol Phys | 2017 | 98 | 206–214 | 28586961 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. | Fizazi, K ; Tran, N ; Fein, L ; Matsubara, N ; Rodriguez-Antolin, A ; Alekseev, BY & al | N Engl J Med | 2017 | 377 | 352–360 | 28578607 |
Percutaneous radiofrequency ablation of lung metastases from colorectal carcinoma under C‑arm cone beam CT guidance. | Amouyal, G ; Pernot, S ; Déan, C ; Cholley, B ; Scotté, F ; Sapoval, M & al | Diagn Interv Imaging | 2017 | 98 | 793–799 | 28571704 |
Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach. | Scotté, F | Ann Oncol | 2017 | 28 | 1165–1167 | 28398565 |
Partnering with patients in translational oncology research: ethical approach. | Mamzer, MF ; Duchange, N ; Darquy, S ; Marvanne, P ; Rambaud, C ; Marsico, G & al | J Transl Med | 2017 | 15 | 74 | 28390420 |
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. | Dieras, V ; Pop, S ; Berger, F ; Dujaric, ME ; Beuzeboc, P ; Escalup, L & al | Anticancer Res | 2017 | 37 | 1403–1407 | 28314310 |
Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. | Farina, P ; Tabouret, E ; Lehmann, P ; Barrie, M ; Petrirena, G ; Campello, C & al | J Neurooncol | 2017 | 132 | 433–437 | 28265824 |
Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer. | Labidi, S ; Mejri, N ; Lagha, A ; Daoud, N ; El Benna, H ; Afrit, M & al | Breast Care (Basel) | 2016 | 11 | 418–422 | 28228709 |
Supportive Care Organization in France: a national in-depth survey among patients and oncologists. | Scotté, F ; Hervé, C ; Leroy, P ; Tourani, JM ; Bensadoun, RJ ; Bugat, ME & al | Support Care Cancer | 2017 | 25 | 2111–2118 | 28220314 |
[Current events in immunotherapy for upper aerodigestive tract cancer]. | Outh-Gauer, S ; Le Tourneau, C ; Broudin, C ; Scotte, F ; Roussel, H ; Hans, S & al | Ann Pathol | 2017 | 37 | 79–89 | 28111039 |
Basi cervical inflammatory mass. | Benkhatar, H ; Scotte, F ; Laccourreye, O ; Benoit, C | Eur Ann Otorhinolaryngol Head Neck Dis | 2017 | 134 | 365–367 | 28017542 |
The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. | Carrat, F ; Seksik, P ; Colombel, JF ; Peyrin-Biroulet, L ; Beaugerie, L | Aliment Pharmacol Ther | 2017 | 45 | 533–541 | 27995656 |
Preliminary experience of the concurrent use of radiosurgery and T‑DM1 for brain metastases in HER2-positive metastatic breast cancer. | Geraud, A ; Xu, HP ; Beuzeboc, P ; Kirova, YM | J Neurooncol | 2017 | 131 | 69–72 | 27995546 |
Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study). | Luporsi, E ; Toledano, A ; Spaeth, D ; Scotté, F ; Espié, M ; Perot, S & al | Support Care Cancer | 2017 | 25 | 973–982 | 27915456 |
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). | Necchi, A ; Sonpavde, G ; Lo Vullo, S ; Giardiello, D ; Bamias, A ; Crabb, SJ & al | Eur Urol | 2017 | 71 | 281–289 | 27726966 |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. | Gravis, G ; Audenet, F ; Irani, J ; Timsit, MO ; Barthelemy, P ; Beuzeboc, P & al | Cancer Treat Rev | 2017 | 55 | 211–217 | 27665366 |
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. | Houédé, N ; Locker, G ; Lucas, C ; Parra, HS ; Basso, U ; Spaeth, D & al | BMC Cancer | 2016 | 16 | 752 | 27664126 |
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. | Pouessel, D ; Bastuji-Garin, S ; Houédé, N ; Vordos, D ; Loriot, Y ; Chevreau, C & al | Clin Genitourin Cancer | 2017 | 15 | e45-e52 | 27554584 |
Coping with a newly diagnosed high-grade glioma: patient-caregiver dyad effects on quality of life. | Baumstarck, K ; Leroy, T ; Hamidou, Z ; Tabouret, E ; Farina, P ; Barrié, M & al | J Neurooncol | 2016 | 129 | 155–64 | 27300523 |
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. | Médioni, J ; Di Palma, M ; Guillot, A ; Spaeth, D ; Théodore, C | BMC Cancer | 2016 | 16 | 217 | 26975779 |
Glioblastoma in Tunisia: A retrospective study about 41 cases. | Ben Nasr, S ; Haddaoui, A ; Bach Hamba, S ; Lagha, A ; Labidi, S ; Afrit, M & al | Tunis Med | 2015 | 93 | 598–601 | 26895120 |
Angiopoietin‑2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma. | Labussière, M ; Cheneau, C ; Prahst, C ; Gállego Pérez-Larraya, J ; Farina, P ; Lombardi, G & al | Cancer Invest | 2016 | 34 | 39–44 | 26735326 |
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. | Gravis, G ; Boher, JM ; Joly, F ; Soulié, M ; Albiges, L ; Priou, F & al | Eur Urol | 2016 | 70 | 256–62 | 26610858 |
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. | Blanchard, P ; Faivre, L ; Lesaunier, F ; Salem, N ; Mesgouez-Nebout, N ; Deniau-Alexandre, E & al | Int J Radiat Oncol Biol Phys | 2016 | 94 | 85–92 | 26576711 |
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. | Bourrier, A ; Carrat, F ; Colombel, JF ; Bouvier, AM ; Abitbol, V ; Marteau, P & al | Aliment Pharmacol Ther | 2016 | 43 | 252–61 | 26549003 |
RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. | Beuselinck, B ; Jean-Baptiste, J ; Couchy, G ; Job, S ; De Reynies, A ; Wolter, P & al | Br J Cancer | 2015 | 113 | 1313–22 | 26528707 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). | Aparicio, T ; Lavau-Denes, S ; Phelip, JM ; Maillard, E ; Jouve, JL ; Gargot, D & al | Ann Oncol | 2016 | 27 | 121–7 | 26487578 |
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. | Tournigand, C ; Chibaudel, B ; Samson, B ; Scheithauer, W ; Vernerey, D ; Mésange, P & al | Lancet Oncol | 2015 | 16 | 1493–1505 | 26474518 |
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. | Alentorn, A ; Dehais, C ; Ducray, F ; Carpentier, C ; Mokhtari, K ; Figarella-Branger, D & al | Neurology | 2015 | 85 | 1325–31 | 26385879 |
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. | Fizazi, K ; Faivre, L ; Lesaunier, F ; Delva, R ; Gravis, G ; Rolland, F & al | Lancet Oncol | 2015 | 16 | 787–94 | 26028518 |
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. | Galsky, MD ; Pal, SK ; Chowdhury, S ; Harshman, LC ; Crabb, SJ ; Wong, YN & al | Cancer | 2015 | 121 | 2586–93 | 25872978 |
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. | Ravaud, A ; Oudard, S ; De Fromont, M ; Chevreau, C ; Gravis, G ; Zanetta, S & al | Ann Oncol | 2015 | 26 | 1123–8 | 25802238 |
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma. | Houédé, N ; Dupuy, L ; Fléchon, A ; Beuzeboc, P ; Gravis, G ; Laguerre, B & al | BJU Int | 2016 | 117 | 444–9 | 25601543 |
The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. | Mora, M ; Angelini, C ; Bignami, F ; Bodin, AM ; Crimi, M ; Di Donato, JH & al | Eur J Hum Genet | 2015 | 23 | 1116–23 | 25537360 |
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. | Sternberg, CN ; Skoneczna, I ; Kerst, JM ; Albers, P ; Fossa, SD ; Agerbaek, M & al | Lancet Oncol | 2015 | 16 | 76–86 | 25498218 |
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. | Oudard, S ; Culine, S ; Vano, Y ; Goldwasser, F ; Théodore, C ; Nguyen, T & al | Eur J Cancer | 2015 | 51 | 45–54 | 25459391 |
Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. | Thiery-Vuillemin, A ; Theodore, C ; Jacobasch, L ; Schmitz, J ; Papandreou, C ; Guillot, A & al | Clin Genitourin Cancer | 2015 | 13 | 231–8 | 25456838 |
Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. | Figarella-Branger, D ; Mokhtari, K ; Colin, C ; Uro-Coste, E ; Jouvet, A ; Dehais, C & al | Brain Pathol | 2015 | 25 | 418–28 | 25407774 |
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. | Hebbar, M ; Chibaudel, B ; André, T ; Mineur, L ; Smith, D ; Louvet, C & al | Ann Oncol | 2015 | 26 | 340–7 | 25403578 |
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. | Gravis, G ; Boher, JM ; Fizazi, K ; Joly, F ; Priou, F ; Marino, P & al | Eur Urol | 2015 | 68 | 196–204 | 25277272 |